Several growth factors are trophic for the gastrointestinal tract and able to reduce the degree of intestinal damage caused by cytotoxic agents. However, studies of epidermal growth factor (EGF) for chemotherapy-induced intestinal injury are conflicting. The recent development of a transgenic mouse that specifically overexpresses EGF in the small intestine provided a unique opportunity to assess the contribution of this growth factor in mucositis. After a course of fluorouracil, the transgenic mice fared no better than control mice. Their weight recovery was inferior, and their mucosal architecture was not preserved. Apoptosis was not decreased and proliferation was not increased in their crypts. To corroborate the negative findings in the transgenic mice, ICR mice were treated with exogenous EGF after receiving fluorouracil. These mice were not protected from intestinal damage, despite the ileal upregulation of native and activated EGF receptor in these animals. Furthermore, no benefits were observed with alternate doses, schedules, or routes of administration of EGF. Finally, mucositis was induced in mutant mice with specific defects of the EGF signaling axis. When compared to control mice, clinical and histological parameters of intestinal injury after fluorouracil were no different in waved-2 mice, which possess functionally diminished EGF receptors, or waved-1 mice, which lack transforming growth factor α, another major ligand for the EGF receptor. These findings do not support a critical role for EGF or its receptor in chemotherapy-induced intestinal injury.
INTRODUCTION
Chemotherapy-induced intestinal injury, commonly referred to as mucositis, is a major cause of morbidity and mortality during therapy for cancer. This problem has become more clinically relevant as oncologists have intensified chemotherapeutic regimens in an effort to improve long-term survival (1) . Neutropenic enterocolitis represents the most severe manifestation of this complication, and has an incidence and mortality as high as 32% and 45%, respectively (16, 34) .
Mucositis is characterized by the loss of intestinal mucosal integrity that results from the widespread apoptosis and death of regenerative stem cells secondary to chemotherapy (29) . The ensuing damage includes perturbed brush border hydrolase activity (28) , reduced mucosal DNA, RNA, and protein content (25) , blunted villus heights and crypt depths (7, 10) , and decreased proliferation (7, 10, 32) and increased apoptosis of crypt cells (27) . Additionally, there is an increase in mucosal permeability (15, 25, 32) , an important predisposing factor to the translocation of bacteria from the intestinal lumen to the bloodstream and distant organs (2, 3) .
These cellular changes ultimately result in a clinical syndrome of diarrhea, intestinal blood loss, dehydration, impaired nutrition, weight loss, and disseminated infections (7, 10, 15) .
Several growth factors have been studied for their potential to attenuate or even nullify cytotoxic intestinal injury (5, 14, 30, 36, 38) . Interleukin-11 (IL-11) and keratinocyte growth factor (KGF) have been the recent focus of investigation, and the results of initial studies are promising. They appear to confer significant protection upon the gastrointestinal tract from cytoablative therapy (7, 10, 26, 27) . These findings have been replicated in other models of intestinal injury (6, 17, 20, 31, 33, 40) . Epidermal growth factor (EGF) also exerts beneficial 4 effects in these models (4, 18, 19, 21, 39) , but its role in mucositis has not been studied extensively and its efficacy remains unclear (13, 28, 32, 35) .
Erwin and his colleagues have created a transgenic mouse that constitutively overexpresses EGF (9) . By joining the promoter for rat intestinal fatty acid-binding protein and the coding sequence for murine EGF, they designed a construct that targeted overexpression exclusively to the villus enterocytes of the jejunum and ileum. Intestinal EGF levels were approximately 60% higher in the transgenic mice when compared to nontransgenic littermates.
Furthermore, these levels were physiologically significant, and provided a clinical advantage.
Following a small bowel resection, the DNA and protein content and villus heights and crypt depths of the remnant intestine were increased in the transgenic mice, findings that are consistent with enhanced adaptation.
This study exploited the intestine-specific overexpression of EGF in these transgenic mice in order to evaluate the effects of this growth factor in chemotherapy-induced intestinal injury. In separate experiments, fluorouracil-treated ICR mice were administered either subcutaneous EGF or albumin, and the degree of intestinal injury was measured. The expression of EGF receptor in the intestine of these animals after fluorouracil also was investigated. Finally, mucositis was induced in two mutant murine strains with different defects of the EGF signaling axis. The significance of the EGF receptor was tested in waved-2 mice, which possess an abnormal EGF receptor with markedly decreased activity (22) . Waved-1 mice, which are deficient in transforming growth factor α (TGFα), were used to assess the contribution of another major ligand for the EGF receptor (23, 24) .
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METHODS
Animals
The protocol for this study was approved by the Children's Hospital Research Foundation Institutional Animal Care and Use Committee. Mice homozygous for a transgene that results in the targeted overexpression of murine EGF in the small intestine were utilized. The genotype of these transgenic mice was confirmed by PCR of DNA isolated from ear clips as previously described (9) . FVB mice (Taconic, Germantown, NY) served as background strain controls. ICR mice (Harlan, Indianapolis, IN) were used in experiments involving exogenous EGF. Studies with the waved-2 and waved-1 strains (The Jackson Laboratory, Bar Harbor, ME) included C57BL/6 mice (The Jackson Laboratory) as controls. All mice were male, 25-30 g in weight, housed in groups of 4 at 21°C on 12 hour day and night cycles, fed standard rodent chow ad libitum, and allowed to acclimate to their environment for at least 4 days before experimentation.
Experimental Designs
After confirming the ileal overexpression of the EGF construct in the transgenic mice by RT-PCR, the transgenic and FVB strains were given either fluorouracil or saline for 4 days. In one set of experiments, the mice were weighed and observed for toxicity during and after the chemotherapy or vehicle for 9 days. In another set of experiments, the mice were sacrificed 2 days after the completion of the course of fluorouracil or saline, and their ileum was harvested and then prepared for the histological studies.
The ICR mice were given fluorouracil as a single dose and then treated with either exogenous EGF or albumin daily until the end of the experiment. In the first set of experiments, weights were recorded and toxicity was monitored for 14 days. In the second set of experiments, 6 ileum was harvested 2, 4, 8, and 12 days after the administration of the fluorouracil and then prepared for the histological studies and Western blot analysis.
The waved-2, waved-1, and C57BL/6 mice were administered a single dose of fluorouracil or saline, and their weights and clinical status were followed for 20 days. Ileum was obtained from another cohort of mice 4 and 20 days after the fluorouracil or saline for the histological studies.
The experimental days on which to perform more detailed histological analyses were chosen in order to coincide with the intestinal injury and repair phases that follow the administration of fluorouracil. These phases were determined from the weight and survival curves, which vary with murine strain, and the different time points for each of the experiments reflect this biological variability.
Fluorouracil and EGF Administration
The fluorouracil (Sigma Chemical Company, St. Louis, MO) was diluted in saline that was adjusted to pH 10 with sodium hydroxide. A total of 200 mg/kg as 4 consecutive daily doses of 50 mg/kg was administered intraperitoneally to the transgenic and FVB mice. The ICR mice received a single dose of 200 mg/kg. The waved-2, waved-1, and C57BL/6 mice received a single dose of 225 mg/kg. These fluorouracil dosages were chosen to effect a similar degree of intestinal damage and clinical toxicity among the various strains of mice, and were determined in separate dose-toxicity experiments that were based, in part, on fluorouracil dosages that have been established by other investigators (7, 10 ). An equal volume of the basic saline vehicle was given to the mice that were not assigned to receive chemotherapy.
The EGF (Chiron Corporation, Emeryville, CA) was diluted in saline, and a dose of 100 µg/kg was injected subcutaneously daily until the end of the experiment. An equal volume of 1% BSA (Life Technologies, Grand Island, NY) was given to the mice that were not randomized to receive EGF. All injections were performed under brief inhaled isoflurane anesthesia.
Tissue Harvest
All mice were sacrificed with an intramuscular injection of a ketamine:xylazine:acepromazine cocktail (4:1:1 proportion) followed by cervical dislocation. A 6 cm section of distal ileum immediately adjacent to the ileocecal valve was excised. The distal 1 cm portion was placed in 10% buffered formalin acetate for the histological studies, and the 
Apoptosis
The hematoxylin/eosin-stained sections also were used to assess crypt apoptosis. The ratio of the number of crypt cells with the morphological features of apoptosis (nuclear condensation and segmentation, cell shrinkage, and apoptotic bodies) to the total number of cells in a crypt was determined for at least 20 crypts for each sample, and the values were averaged to produce the mean percentage of crypt apoptosis.
Proliferation
Proliferation of the crypt cells was detected with a monoclonal antibody for proliferating cell nuclear antigen (PCNA) using a commercial kit (Zymed Laboratories, South San Francisco, 
Western Blot Analysis
The ileal samples were homogenized and then purified by ultracentrifugation at 50,000 × Lysates from A431 cells and EGF-stimulated A431 cells (Transduction Laboratories) were used as positive controls.
Statistical Analysis
Results are expressed as the mean ± SEM. Analyses of the results were performed with statistical software (SigmaStat, SPSS, Chicago, IL). Statistical differences were determined with an unpaired t test or a two-way ANOVA followed by pairwise comparisons utilizing a StudentNewman-Keuls test. A p value less than 0.05 was considered significant.
RESULTS
To validate the primary characteristic of these transgenic mice, EGF construct expression in the jejunum and distal ileum was assessed by RT-PCR. Consistent with the original description of these animals, EGF construct was present in the jejunum of the transgenic mice ( Figure 1) . Of particular note, EGF construct also was observed in the distal ileum. As expected, no EGF construct was evident in the jejunum or distal ileum of the FVB mice. The expression of EGF construct in the distal ileum of the transgenic mice, albeit somewhat less than that of the jejunum, justifies the use of this intestinal segment and this transgenic murine strain in these experiments.
The transgenic and FVB mice developed diarrhea, dehydration, anorexia, and weight loss upon receiving 200 mg/kg of fluorouracil. Despite these clinical findings, the survival rate was 100%. The pattern of initial weight loss was similar for the transgenic and FVB mice ( Figure 2 ).
Weight loss started on the fourth experimental day and reached a maximum of approximately 10% by the sixth day. However, the pattern of subsequent weight recovery differed significantly.
The FVB mice rapidly returned to their baseline weight, fully recovering by the eighth day. In contrast, the transgenic mice regained their weight more slowly and incompletely, ultimately recovering only 50% of their weight loss. The transgenic and FVB mice that were administered saline were asymptomatic, and did not have weight loss.
In separate experiments, transgenic and FVB mice were given fluorouracil as described, but they were sacrificed and their ileum harvested on the sixth experimental day, coincident with the time of maximal weight loss and before the start of weight recovery. Histological manifestations of chemotherapy-induced damage were evident in the tissue sections from the 12 transgenic and FVB mice ( Figures 3C, 3D) . Distortion of the mucosal architecture, particularly of the villi, was readily apparent. Blunting of the villi and sloughing of the enterocytes into the intestinal lumen were present. These findings were absent in the transgenic and FVB mice that received saline ( Figures 3A, 3B) .
Measurements of the villus heights and crypt depths substantiated the histological observations. The villus heights of the fluorouracil-treated mice were significantly shorter when compared to mice that were given saline, demonstrating the injurious effects of the chemotherapy upon the ileum ( Figure 4A ). In contrast, the crypt depths were greater in the mice that received fluorouracil, reflecting the intestinal response that follows injury and precedes repair ( Figure 4B ). However, neither the villus heights nor the crypt depths were significantly different after the administration of fluorouracil in the transgenic mice when compared to FVB mice. These results were confirmed with crypt depth to villus height ratios, which afford greater precision ( Figure 4C ).
Because chemotherapeutic agents preferentially target rapidly dividing cells, including those of the intestinal crypt, the extent of apoptosis in the crypts was evaluated as another parameter of intestinal damage. A 5-fold increase in crypt apoptosis was induced in the mice that were treated with fluorouracil, but apoptosis was not decreased in the transgenic mice when compared to FVB mice ( Table 1) . As observed with the crypt depths, significant increases in intestinal stem cell proliferation were seen in both strains of mice after receiving fluorouracil.
However, crypt proliferation was not augmented in the transgenic mice when compared to FVB mice ( Table 1) . Similar results were obtained when the magnitude of crypt apoptosis and proliferation was expressed as an absolute value (number of apoptotic or PCNA-positive cells per crypt).
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To corroborate the negative findings in the transgenic mice, experiments with exogenously administered EGF were performed in ICR mice given fluorouracil. When compared to mice that received albumin, no improvements in the survival rate were seen with EGF ( Figure   5A ). Although no differences in weight were observed initially, the EGF-treated mice developed an advantage in weight 6 to 10 days after the fluorouracil ( Figure 5B) . Utilizing another cohort of mice, histological parameters were evaluated during both the injury and repair phases subsequent to the fluorouracil. With the singular exception of the villus heights 4 days after the fluorouracil, treatment with EGF did not result in preserved villus heights ( Figure 6A ), attenuated crypt apoptosis ( Figure 6B ), or enhanced crypt proliferation ( Figure 6C ) at any time point after the chemotherapy. The increased villus heights of the mice that were administered EGF were not sustained beyond the fourth experimental day, and no other significant changes were demonstrated during the repair phase.
The ileum of these mice also were assayed for the expression of EGF receptor ( Figure 7) .
There was not a significant upregulation of native EGF receptor or its tyrosine-phosphorylated, activated form at any time point in the mice that were given albumin after the fluorouracil when compared to unperturbed mice that received no chemotherapy. However, as expected, the mice To exclude the possibility that an alternative dose, schedule, or route of administration of EGF would be more beneficial, mucositis was induced in ICR mice with 500 mg/kg of fluorouracil and the effect of these variables was investigated. No dose (50-10,000 µg/kg/d), schedule (before, during, and after the fluorouracil), or route of administration (subcutaneous and orogastric) of EGF was found to increase the survival rate or decrease the amount of weight loss (data not shown).
As another means of assessing the significance of the EGF receptor, the effect of a functionally attenuated EGF receptor during and after mucositis was studied in waved-2 mice.
Except for a period of time from the eighth to the thirteenth experimental day during which the waved-2 mice had significantly greater weights than the C57BL/6 mice, both murine strains had nearly identical clinical courses after receiving fluorouracil, with similar survival rates ( Figure   8A ) and patterns of weight loss ( Figure 8B) . In separate experiments, the ileum of these mice were examined during and after the intestinal injury resulting from the fluorouracil. The villus heights of the waved-2 mice were not significantly different at any time point when compared to C57BL/6 mice ( Figure 8C ). The mice that received saline did not exhibit any clinical toxicity or histological damage. Similar responses were seen when the contribution of another major ligand for the EGF receptor was evaluated in waved-1 mice. No differences in survival rates ( Figure 9A ), weight loss ( Figure 9B ), or villus heights ( Figure 9C) were noted between the waved-1 and C57BL/6 mice after fluorouracil.
DISCUSSION
To address the questions that have arisen regarding the efficacy of EGF in mucositis, this study employed different but complementary experimental approaches to establish that this growth factor has a limited role in chemotherapy-induced intestinal injury. First, the experimental design of all prior investigations of EGF and mucositis have been based upon and restricted to the exogenous administration of the growth factor (13, 28, 32, 35) . In addition to extensive tests of exogenous EGF, this study utilized transgenic mice that overexpress EGF in the small intestine and mutant mice that lack TGFα to demonstrate that neither EGF nor alternate ligands for the EGF receptor contributes significantly to the prevention or repair of intestinal damage caused by chemotherapy. Second, the status of the EGF receptor in mucositis has not been assessed previously. This study revealed that neither the activation of this receptor by Using biochemical parameters, Petschow and his associates concluded differently and showed that EGF accelerates the recovery of intestinal brush border hydrolase activities after methotrexate in rats (28) . Animals that received EGF in their liquid diet had more normal levels of leucine aminopeptidase, maltase, and sucrase activity in the middle portion of their small intestine 6 days after the chemotherapy. Interestingly, higher doses of EGF resulted in blunted levels of disaccharidase activity in the same section of intestine, revealing a possible dose limit.
Hirano and his colleagues also found that EGF facilitates intestinal mucosal recovery after methotrexate in rats (13) . The activity of ornithine decarboxylase, an enzyme that participates in the repair of damaged rat intestinal mucosa, occurred earlier and was greater in animals that were given intraperitoneal injections of EGF. Sonis and his coworkers reported that EGF actually exacerbates oral mucositis in hamsters (35) . When a continuous infusion of EGF to the oral cavity was initiated after the induction of mucositis by intraperitoneal fluorouracil and oral trauma, severity scores based upon the gross appearance of the buccal mucosa were significantly higher.
In contrast to those of EGF, studies of other growth factors have been uniformly positive.
Du and her coworkers demonstrated that IL-11 can stimulate recovery of the intestinal mucosa, reduce the dissemination of enteric bacteria to distant organs, and increase survival in mice after combined chemotherapy and radiotherapy (7) . In another series of experiments, these investigators showed that the intestinal regeneration that is mediated by IL-11 occurs not only through increased proliferation but also decreased apoptosis of the crypt cells (27) . Opal and his associates found that the combination of IL-11 and granulocyte colony-stimulating factor provides additive protection against infectious complications related to intestinal damage after chemotherapy (26). Farrell and her colleagues discovered that KGF also reduces the morbidity and mortality of mucositis by stimulating crypt cell proliferation and enhancing crypt survival The discordant results that have been obtained with EGF and the preponderance of positive data that has been generated by other growth factors have been difficult to reconcile, and prompted the experiments in this study.
The use of a transgenic mouse to evaluate the efficacy of a growth factor in chemotherapy-induced intestinal injury is novel. The primary advantage of this experimental approach is the minimization of confounding factors that are introduced with the exogenous delivery of any substance, particularly the stress that is associated with orogastric, subcutaneous, or intraperitoneal administration in animals (28) . The organ-specific restriction of the growth factor of interest also reduces any systemic effects that may result when the exogenous form is given enterally or parenterally (9) . The EGF-overexpressing transgenic mice that were utilized in this study possessed both of these advantages, and their outcome after fluorouracil strongly suggests that EGF does not exert a beneficial effect in chemotherapy-induced intestinal injury.
The lack of protection from mucositis in the transgenic mice may be related to the constitutive pattern of EGF expression by the enterocytes on the villi. The continuous production of growth factor effectively provides these enterocytes with EGF stimulation before, during, and after their exposure to the fluorouracil. These constitutively activated enterocytes may have been made more susceptible to the effects of the fluorouracil, nullifying any potential benefit of the EGF. A sufficiently significant loss of enterocytes also would have rendered the continued presence of EGF after the clearance of fluorouracil ineffective. However, this possibility is difficult to support given the negative findings in the ICR mice, which did not receive EGF until the dose of fluorouracil was delivered. Furthermore, no improvements were seen in these mice when various changes to the timing of the exogenous EGF to the fluorouracil were made.
A suboptimal intestinal concentration of EGF is another possible explanation for the inability of the transgenic mice to prevent or minimize the chemotherapy-induced intestinal damage. However, when Erwin and his coworkers initially characterized this strain, they found that the EGF level in intestinal homogenates was approximately 60% higher than that of the nontransgenic mice (9) . When the transgenic mice were subjected to a small bowel resection, this EGF level resulted in the augmentation of the postoperative adaptive response in their remnant ileum. Therefore, independent of the amount of EGF that these animals actually overexpress in their small intestine, the effects of the EGF transgene translate into measurable physiological changes. In fact, the adaptive advantage afforded by this transgene in a model of small bowel resection only highlights the significance of the lack of protection that it provides from mucositis. Furthermore, as with the various schedules of EGF administration, a wide range of EGF doses were tested in the ICR mice, and no benefit was observed.
Although significantly increased weights were noted in the ICR mice that received exogenous EGF 6 to 10 days after the fluorouracil, they were not associated with concurrent benefits at a histological level, such as augmented villus heights, attenuated crypt apoptosis, or enhanced crypt proliferation. Therefore, it is difficult to attribute the weight improvement to intestinal protection by EGF. An isolated increase in the villus heights of these mice was observed 4 days after the fluorouracil, but the clinical significance of this singular histological finding is diminished by the lack of a concomitant advantage in weight or survival at the same time point. There also was not a decrease in crypt apoptosis or increase in crypt proliferation preceding the increased villus heights, which would be expected as part of the biological sequence of events. Additionally, this augmentation was unsustained, with the difference in villus heights between the EGF-treated and albumin-treated mice being insignificant by the eighth and twelfth experimental days. When considered as a whole, the weight and villus height data are not sufficient pieces of evidence for consistent and durable protection from mucositis with exogenous EGF. Furthermore, no advantage was seen at any time point for the other clinical and histological parameters of intestinal injury, including survival rate, crypt apoptosis, and crypt proliferation. These lines of analysis strongly suggest that the isolated weight and villus height findings represent a statistical aberration and not a relevant physiological event.
The Waved-2 mice express a defective receptor, and, therefore, are insensitive to all of the ligands in the EGF family. In this study, redundancy along the EGF signaling axis may account for the absence of toxicity that was observed in the waved-1 mice after chemotherapy. If such a redundancy is operative in the biology of mucositis, even aaeett mice may not exhibit significant gastrointestinal damage secondary to chemotherapy. However, the contribution of alternate ligands cannot explain the lack of injury that was seen in the waved-2 mice that received fluorouracil. The outcome of the waved-2 mice suggests that it is unlikely that any of the ligands in the EGF family can alter the course of chemotherapy-induced intestinal injury.
Various chemotherapeutic agents, including melphalan (32), methotrexate (13, 28) , and fluorouracil (35) , have been utilized in previous studies of EGF for mucositis. The variable results of these studies implicate the choice of chemotherapeutic agent as an explanation for the disparate outcomes. First, the use of fluorouracil as a potent and reliable inducer of intestinal injury is not unique to this study. Investigators of other growth factors with therapeutic efficacy in mucositis also have employed fluorouracil, which suggests that it does not possess a particular activity that renders its damage uniformly unamenable to the action of growth factors (7, 10, 36) .
Second, the use of melphalan, an alkylator, instead of fluorouracil, a nucleoside analogue, by
Robinson and his coworkers weakens any argument that the lack of benefit of EGF in chemotherapy-induced intestinal injury is primarily attributable to a specific chemotherapeutic agent (32) . Finally, it is not likely that the negative findings of this study are the result of a distinct action of fluorouracil upon EGF or its receptor because the Western blot analysis demonstrates that upregulation and activation of EGF receptor by exogenous EGF still occur after fluorouracil.
In addition to the studies that have been conducted in animals, Girdler and his associates tested the effects of a mouthwash containing EGF in humans that were receiving stomatotoxic chemotherapy (11) . They found that the EGF solution did not reduce the number or size of the oral ulcers when compared to placebo. Although methodological considerations make direct comparisons to this study difficult, their conclusion is consistent with the results of these experiments. 
